ATE337005T1 - Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis - Google Patents

Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis

Info

Publication number
ATE337005T1
ATE337005T1 AT02800625T AT02800625T ATE337005T1 AT E337005 T1 ATE337005 T1 AT E337005T1 AT 02800625 T AT02800625 T AT 02800625T AT 02800625 T AT02800625 T AT 02800625T AT E337005 T1 ATE337005 T1 AT E337005T1
Authority
AT
Austria
Prior art keywords
psoriasis
prevention
treatment
nail polish
polish containing
Prior art date
Application number
AT02800625T
Other languages
English (en)
Inventor
Pascal Lefrancois
Roger Riveneuve De Cri Navarro
Marlene Delaunois
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Application granted granted Critical
Publication of ATE337005T1 publication Critical patent/ATE337005T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
AT02800625T 2001-10-05 2002-10-03 Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis ATE337005T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0112825A FR2830449B1 (fr) 2001-10-05 2001-10-05 Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant

Publications (1)

Publication Number Publication Date
ATE337005T1 true ATE337005T1 (de) 2006-09-15

Family

ID=8867960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800625T ATE337005T1 (de) 2001-10-05 2002-10-03 Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis

Country Status (9)

Country Link
US (1) US20050002878A1 (de)
EP (2) EP1432414B1 (de)
JP (1) JP2005505593A (de)
AT (1) ATE337005T1 (de)
CA (1) CA2462579A1 (de)
DE (1) DE60214207T2 (de)
ES (1) ES2271373T3 (de)
FR (1) FR2830449B1 (de)
WO (1) WO2003030896A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021968A2 (en) 2002-09-05 2004-03-18 Galderma Research & Development, S.N.C. Solution for ungual application
DE10358091A1 (de) * 2003-12-10 2005-07-14 Eckart Gmbh & Co. Kg Kosmetische Zusammensetzung zur Erzeugung eines kosmetischen Überzugs mit einem metallisch und mehrfarbig schillernden Erscheinungsbild und künstlicher Fingernagel
KR101536806B1 (ko) * 2009-07-16 2015-07-14 스티펠 래버러토리즈, 인코포레이티드 타자로텐 유도체
US8492454B2 (en) 2009-10-05 2013-07-23 Creative Nail Design, Inc. Removable color layer for artificial nail coatings and methods therefore
US8263677B2 (en) * 2009-09-08 2012-09-11 Creative Nail Design, Inc. Removable color gel basecoat for artificial nail coatings and methods therefore
US8541482B2 (en) * 2009-10-05 2013-09-24 Creative Nail Design, Inc. Removable multilayer nail coating system and methods therefore
WO2012121704A1 (en) * 2011-03-07 2012-09-13 Creative Nail Design, Inc. Compositions and methods for uv-curable cosmetic nail coatings
EP2612665A1 (de) 2012-01-09 2013-07-10 Almirall S.A. Topische pharmazeutische Zusammensetzungen enthaltend Bexaroten und ein Kortikosteroid
CN107296809A (zh) * 2016-04-15 2017-10-27 厦门恩成制药有限公司 一种治疗银屑病的外用药物组合物
CN107468637A (zh) * 2016-06-08 2017-12-15 厦门恩成制药有限公司 复方他扎罗汀尿素外用制剂及其制备方法
KR102082761B1 (ko) * 2018-10-22 2020-02-28 주식회사 대림 수용성 미네랄을 함유하는 화장품 조성물 및 그 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250164A (en) * 1979-04-09 1981-02-10 Bernstein Joel E Method of treating psoriasis of the nails and composition
DE4212105A1 (de) * 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
RO118174B1 (ro) * 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use

Also Published As

Publication number Publication date
EP1695707A1 (de) 2006-08-30
DE60214207D1 (de) 2006-10-05
EP1432414A1 (de) 2004-06-30
US20050002878A1 (en) 2005-01-06
CA2462579A1 (fr) 2003-04-17
ES2271373T3 (es) 2007-04-16
EP1432414B1 (de) 2006-08-23
FR2830449B1 (fr) 2004-04-23
JP2005505593A (ja) 2005-02-24
WO2003030896A1 (fr) 2003-04-17
DE60214207T2 (de) 2007-10-11
FR2830449A1 (fr) 2003-04-11

Similar Documents

Publication Publication Date Title
ATE408601T1 (de) Fredericamycin-derivate
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE214933T1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE337005T1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60022070D1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
DE50306258D1 (de) Topische verwendung von diuretika zur behandlung von schwellungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1432414

Country of ref document: EP

REN Ceased due to non-payment of the annual fee